TEL AVIV (Reuters) Galmed Pharmaceuticals said on Tuesday patients in a mid-stage trial for its treatment for NASH, a fatty liver disease linked to obesity, showed a statistically significant reduction in liver fat The results will allow Galmed to meet with regulators as soon as possible and discuss a pivotal Phase 3 study design, Galmed […]

The post Israeli Company Galmed Gets Positive Trial Results for Liver Drug appeared first on OMG News Today.